What is Haemonetics's cumulative cost basis?

Haemonetics (HAE) reported cumulative cost basis of $836.81M in Q4 2025.

How has Haemonetics's cumulative cost basis changed year-over-year?

Haemonetics's cumulative cost basis decreased by 3.5% year-over-year, from $867.46M to $836.81M.

What is the long-term trend for Haemonetics's cumulative cost basis?

Over 2 years (2023 to 2025), Haemonetics's cumulative cost basis has grown at a -5.8% compound annual growth rate (CAGR), from $944.22M to $837.19M.

Haemonetics HAE Cumulative Cost Basis

Cumulative Cost Basis at other companies

AbbottABT

——

Bio-Rad LaboratoriesBIO

——

Becton, Dickinson and CompanyBDX

——

Merit Medical SystemsMMSI

——

StrykerSYK

——

Other financials

Income statement

See full

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

See full

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

See full

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

See full

Market cap$3.31B-18.0%

Profitability

See full

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The official record: Haemonetics’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Haemonetics's cumulative cost basis?: Haemonetics (HAE) reported cumulative cost basis of $836.81M in Q4 2025.
How has Haemonetics's cumulative cost basis changed year-over-year?: Haemonetics's cumulative cost basis decreased by 3.5% year-over-year, from $867.46M to $836.81M.
What is the long-term trend for Haemonetics's cumulative cost basis?: Over 2 years (2023 to 2025), Haemonetics's cumulative cost basis has grown at a -5.8% compound annual growth rate (CAGR), from $944.22M to $837.19M.